Patent Review (2017-2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases

• Egile Nagusiak: Dionysios V. Chartoumpekis (Egilea), Chun-Yan Fu (Egilea), Panos G. Ziros (Egilea), Gerasimos P. Sykiotis (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2020-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Research on the antioxidant pathway comprising the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and its cytoplasmic inhibitor Kelch-like ECH-associated protein 1 (Keap1) is ever increasing. As modulators of this pathway have started to be used in clinical trials and clinic...